More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
Maria FleseriuDagmar Führer-SakelAart J van der LelyLaura De MarinisThierry BrueJoli van der Lans-BussemakerJudith Hey-HadaviCecilia Camacho-HubnerMichael P WajnrajchSrinivas Rao ValluriAndrew Anthony PalladinoRoy GomezRoberto SalvatoriPublished in: European journal of endocrinology (2021)
This comprehensive review of the complete cohort in ACROSTUDY confirmed the overall favourable benefit-to-risk profile and high efficacy of PEGV as mono- and combination therapy in patients with an aggressive course/uncontrolled/active acromegaly requiring long-term medical therapy for control.